Μετάβαση στο περιεχόμενο

ΕτικέταCLL

Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling History

Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs … Continue Reading Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling History